SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla inches up on expanding partnership with Roche Pharma

18 Jun 2020 Evaluate
Cipla is currently trading at Rs. 641.10, up by 0.60 points or 0.09% from its previous closing of Rs. 640.50 on the BSE.
 
The scrip opened at Rs. 638.00 and has touched a high and low of Rs. 644.20 and Rs. 636.75 respectively. So far 53135 shares were traded on the counter.
 
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 669.65 on 05-Jun-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.
 
Last one week high and low of the scrip stood at Rs. 653.15 and Rs. 618.85 respectively. The current market cap of the company is Rs. 51516.69 crore.
 
The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 40.61% and 22.71% respectively.
 
Roche Pharma India has expanded its partnership with domestic pharma major Cipla to further improve access to its key oncology medicines in India. Roche Pharma India has signed a distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distribution of its trademark oncology drugs - trastuzumab (Herclon), bevacizumab (Avastin) and rituximab (Ristova) in India.
 
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1326.65 -8.20 (-0.61%)
05-May-2026 13:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1815.30
Dr. Reddys Lab 1271.50
Cipla 1326.65
Zydus Lifesciences 910.55
Lupin 2345.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×